Cumulus Neuroscience

This week at #ADPD2025, Cumulus Neuroscience presented validation data confirming that patients are willing and able to perform repeated cognitive and EEG testing at home to collect high quality data, and two novel NeuLogiq Platform endpoints show greater separation with Alzheimer’s pTau217 pathology than the benchmark Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog). A second data set provided initial evidence that the NeuLogiq Platform can capture speech fluency and emotion recognition decline in patients living with ALS, offering potential utility as a digital biomarker of cognitive decline. #Alzheimers #endalz #ADresearch #ALS #FTD #digitalhealth #CNS #decentralizedclinicaltrials #clinicaltrials Read more: https://lnkd.in/eybDaSeP

This week, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) – of which Cumulus Neuroscience is a partner – launched valuable new resources from its “Building the business case for digital endpoints” project. Importantly, the resources listed below incorporate findings from DiMe’s partnership with the Tufts Center for the Study of Drug Development and will enable stakeholders across the life sciences industry to demonstrate the value of digital endpoints in clinical trials: - Digital Endpoints Value Framework - Digital Endpoints ROI Calculator - Digital Endpoints Business Case Template - Value of Digital Endpoints: Case Study Catalog Cumulus Neuroscience is proud of our collaboration with Digital Medicine Society (DiMe) and key stakeholders across industry that worked to bring these resources to life including representatives from pharma, med tech, digital health and the FDA. #digitalendpoints #innovation DATAcc resources: Digital Endpoints Value Framework https://lnkd.in/e9N2TMds Digital Endpoints ROI Calculator https://lnkd.in/evAx_gjm Digital Endpoints Business Case Template https://lnkd.in/einPxSbS Value of Digital Endpoints: Case Study Catalog https://lnkd.in/ea5Eq4-M

Cumulus Neuroscience is pleased to announce acceptance of two posters by the Scientific Program Committee for the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases entitled "Neuropsychological phenotyping of Alzheimer's dementia at home, using the Cumulus NeuLogiq® Platform with plasma biomarkers (SHIFT 02-328)" and "Neurocognitive evaluation from the home: validation of the Cumulus Platform in FTD and ALS populations (SHIFT 02-658)". Cumulus CSO & Co-Founder Brian Murphy, PhD and our Principal Scientist John Dyer, PhD are looking forward to sharing these data with you at #ADPD2025 in Vienna on April 4th & 5th. #alzheimers #CNS #clinicalresearch #digitalendpoints Read more: https://lnkd.in/ddTsgXhM AD/PD™ 2025: https://lnkd.in/dt946dr

Saturday March 8th is International Women’s Day 2025. At Cumulus Neuroscience, nearly 50% of employees are women, including #WomenInSTEM across our Science, Analytics, Engineering, Regulatory & Quality, Business Development & Customer Success teams. We celebrate these talented women and all of the allies at Cumulus and beyond who support them! #IWD2025 #AccelerateAction

George Stothart, PhD, Principal Scientist at Cumulus Neuroscience and Senior Lecturer at the University of Bath had an opportunity to showcase his novel Alzheimer’s screening tool AccelADx when Government Chief Scientific Adviser Professor Dame Angela McLean DBE FRS visited the university last week. Read more: https://lnkd.in/eM5-W48R Professor Dame Angela McLean: https://lnkd.in/eTYehRkQ George Stothart: https://lnkd.in/ed5qRQc7 Image credit: Tim Gander / University of Bath

Join the Cumulus Neuroscience Executive Team for the 8th Annual Neuroscience Innovation Forum at the Marine Memorial Club in San Francisco on Sunday January 12th where Co-Founder and CSO Brian Murphy, PhD will present an overview of our NeuLogiq neuro-assessment platform and our new product in development, AccelADx which has the potential to revolutionize how the earliest signs of Alzheimer's are detected. #CNS #alzheimers #innovation Tina Sampath, Interim CEO Siggi Saevarsson, COO

Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience presented a podium presentation titled “EEG for Everyone - Objective Measure of EEG and Cognition at Scale with the NeuLogiq Platform” and a poster titled “Scalable tools for the non-invasive measurement of neuroplasticity in clinical trials of CNS therapies” at the International Pharmaco-EEG Society for Preclinical and Clinical Electrophysiological Brain Research (IPEG) annual meeting in Izmir, Turkey last week. As EEG and digital measures of behaviour emerge as a key markers in CNS trials, we presented data demonstrating that the platform can be used at scale with a variety of populations to detect the symptomology and mechanisms of disease and therapies in neurology and psychiatry. https://lnkd.in/ecc6RqMS

Cumulus Neuroscience is excited to announce that Brian Murphy, PHD, CSO and Co-founder of Cumulus was featured on the Shot of Digital Health Therapy podcast where he discussed his circuitous journey to becoming a computational neuroscientist, and ultimately how his lack of patience and a desire to measure the brain at scale led him to launch Cumulus. Hosted by digital health veterans Jim Joyce and Eugene Borukhovich, this weekly “meticulously unproduced” podcast features leaders in the field of digital health. Podcast links: Youtube: https://lnkd.in/eGQnPZyW Podcast: https://lnkd.in/dkQ55Rh https://lnkd.in/eZDeAVPi https://lnkd.in/ebY_GJSu

Dementia and Alzheimer’s disease represent a leading cause of death in the UK. There are over 900,000 patients living with dementia in the UK today and as many of you know, there is no cure. Our team is committed to addressing this unmet need by working alongside biopharma to accelerate the development of a new generation of therapies. Importantly, our commitment extends outside the office through participation in local events focused on raising awareness and much needed funding. This year, our small but mighty team raised over £1100+ ($1400+ US) for the Belfast Memory Walk 2024! #MemoryWalk #EndAlzheimers

Cumulus Neuroscience values our strategic partnership with the Digital Medicine Society (DiMe) - join our Co-Founder and CSO Brian Murphy, PhD at 11 AM ET on November 14th for this important launch event where new core digital clinical measures for use in Alzheimer’s Disease and related dementias research will be discussed, along with related resources. #endalzheimers #digitalmeasures #digitalendpoints